LSE:INDV (Indivior PLC)

About INDV

Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs based on buprenorphine for treatment of opioid dependence. The vast majority of Indivior's revenue is generated in the United States, followed by the rest of the world. The company considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
  • Indivior PLC (LSE: INDV) Latest News

    Investing Articles

    These FTSE 250 stocks have plunged 50% in 12 months. Is it time to buy?

    These falling FTSE 250 (INDEXFTSE: MCX) stocks could be worth a look, according to Rupert Hargreaves.

    Read more »

    Investing Articles

    Is Indivior a falling knife to buy after plunging 20%?

    Indivior plc (LON: INDV) shares crash on a profit warning, but is it an oversold bargain to snap up?

    Read more »

    Investing Articles

    Are these the cheapest growth stocks in the FTSE 250?

    Should you buy, sell or hold these two FTSE 250 (INDEXFTSE: MCX) growth stocks?

    Read more »

    Investing Articles

    Why the Indivior share price could be a FTSE 250 buy after today’s 30% fall

    Roland Head looks at the numbers behind today's profit warning from FTSE 250 (INDEXFTSE:MCX) pharma stock Indivior plc (LON:INDV).

    Read more »

    Investing Articles

    2 growth champions I’d buy and hold for two decades

    These companies have room to expand rapidly over the next 20 years.

    Read more »

    Investing Articles

    2 FTSE 250 pharma stocks I’d buy today and hold for another five years

    Roland Head takes a look at two unusual pharma stocks with long-term growth potential.

    Read more »

    Investing Articles

    2 stocks I’d invest £1,000 in right now

    If you are looking for decent share ideas, check out these two that reported on Thursday.

    Read more »

    Investing Articles

    2 no-brainer stocks I’d buy in pharma

    Royston Wild reveals two pharma stocks with the capability to deliver knockout profits growth.

    Read more »

    Investing Articles

    2 monster stocks in the making I’d buy today

    These two shares could post high total returns.

    Read more »

    Investing Articles

    2 growth stocks I’d buy and hold for 2018

    Roland Head takes a look at two promising growth stocks from his watch list.

    Read more »

    Investing Articles

    2 soaring growth stocks I’d consider buying today

    These two stocks have grown strongly in recent years and Harvey Jones expects further progress.

    Read more »

    Investing Articles

    Why this beaten-up FTSE 100 dividend stock could be a bargain

    Roland Head explains why he'd buy this 6% yielder from the FTSE 100 (INDEXFTSE:UKX).

    Read more »